Literature DB >> 23147466

Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.

Yuan-Yuan Qu1, Bo Dai, Yun-Yi Kong, Ding-Wei Ye, Xu-Dong Yao, Shi-Lin Zhang, Hai-Liang Zhang, Chun-Guang Ma, Wei-Yi Yang.   

Abstract

This study aims to evaluate the potential value of patient characteristics in predicting overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel-based thermotherapy. A total of 115 patients with mCRPC undergoing a docetaxel q3w regimen were enrolled in this study. A survival analysis was performed using the Kaplan-Meier method. Cox proportional hazards models were used to evaluate the prognostic value of all covariates for OS. OS was also analysed after stratifying patients according to the results of multivariate analysis. The median OS for the entire cohort was 17.0 months. The multivariate analysis showed that the prostate-specific antigen doubling time (PSADT), baseline haemoglobin (Hb) concentration, alkaline phosphatase (ALP) concentration, cycles of chemotherapy and time to castration resistance were independent prognostic factors of OS. According to the presence of PSADT <46.3 days and baseline ALP ≥ 110 IU l(-1), all patients were divided into three risk groups: low-risk group (no risk factors), intermediate-risk group (one risk factor) and high-risk group (two risk factors). Median OSs for patients in low-, intermediate- and high-risk groups were 28.0 months (95% CI: 23.8-32.2), 21.0 months (95% CI: 18.9-23.1) and 11.0 months (95% CI: 7.6-14.4), respectively (P<0.001). In conclusion, PSADT, baseline Hb concentration, ALP concentration, cycles of chemotherapy and time to castration resistance were independent prognostic factors of OS in Chinese patients with mCRPC treated with docetaxel. PSADT combined with the baseline ALP concentration could be a useful risk stratification parameter for evaluating survival outcomes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23147466      PMCID: PMC3739109          DOI: 10.1038/aja.2012.110

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  20 in total

1.  Natural history of progression after PSA elevation following radical prostatectomy.

Authors:  C R Pound; A W Partin; M A Eisenberger; D W Chan; J D Pearson; P C Walsh
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

2.  Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer.

Authors:  Medha S Darshan; Matthew S Loftus; Maria Thadani-Mulero; Benjamin P Levy; Daniel Escuin; Xi Kathy Zhou; Ada Gjyrezi; Chantal Chanel-Vos; Ruoqian Shen; Scott T Tagawa; Neil H Bander; David M Nanus; Paraskevi Giannakakou
Journal:  Cancer Res       Date:  2011-07-28       Impact factor: 12.701

3.  Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy.

Authors:  Guru Sonpavde; Gregory R Pond; William R Berry; Ronald de Wit; Andrew J Armstrong; Mario A Eisenberger; Ian F Tannock
Journal:  Urol Oncol       Date:  2010-10-02       Impact factor: 3.498

4.  Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

Authors:  Susan Halabi; Eric J Small; Philip W Kantoff; Michael W Kattan; Ellen B Kaplan; Nancy A Dawson; Ellis G Levine; Brent A Blumenstein; Nicholas J Vogelzang
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 44.544

5.  Does PSADT after radical prostatectomy correlate with overall survival?--a report from the SEARCH database group.

Authors:  Anna E Teeter; Joseph C Presti; William J Aronson; Martha K Terris; Christopher J Kane; Christopher L Amling; Stephen J Freedland
Journal:  Urology       Date:  2010-12-08       Impact factor: 2.649

6.  Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival.

Authors:  Evangelos Bournakis; Eleni Efstathiou; Andreas Varkaris; Sijin Wen; Michael Chrisofos; Charalambos Deliveliotis; Christos Alamanis; Ioannis Anastasiou; Constantine Constantinides; Aristotelis Bamias; Meletios A Dimopoulos
Journal:  Anticancer Res       Date:  2011-04       Impact factor: 2.480

7.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Authors:  Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

8.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

9.  Individualized prostate biopsy strategy for Chinese patients with different prostate-specific antigen levels.

Authors:  Bo Dai; Ding-Wei Ye; Yun-Yi Kong; Yi-Jin Shen; Bo-Hua Wang
Journal:  Asian J Androl       Date:  2007-12-20       Impact factor: 3.285

10.  Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.

Authors:  Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

View more
  17 in total

Review 1.  [Biomarker docetaxel-based chemotherapy].

Authors:  D Pfister; A Heidenreich; D Porres
Journal:  Urologe A       Date:  2013-09       Impact factor: 0.639

2.  CIP2A mediates prostate cancer progression via the c-MYC signaling pathway.

Authors:  Zexiong Guo; Dehao Liu; Zexuan Su
Journal:  Tumour Biol       Date:  2015-01-06

3.  CIP2A mediates prostate cancer progression via the c-Myc signaling pathway.

Authors:  Zexiong Guo; Dehao Liu; Zexuan Su
Journal:  Tumour Biol       Date:  2015-01-31

4.  CC-chemokine receptor 7 is overexpressed and correlates with growth and metastasis in prostate cancer.

Authors:  Yongqian Chen; Ye Tian; Zhengguo Ji; Zhi Liu; Donghao Shang
Journal:  Tumour Biol       Date:  2015-02-15

5.  Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize metastatic castration-resistant prostate cancer cells to cabazitaxel chemotherapy.

Authors:  Jinming Huang; Jiaoyuan Jia; Qiang Tong; Jun Liu; Jun Qiu; Rong Sun; Lixin Yao; Chun Yang
Journal:  Tumour Biol       Date:  2014-11-07

6.  Prognostic factors of first-line docetaxel treatment in castration-resistant prostate cancer: roles of neutrophil-to-lymphocyte ratio in patients from Northwestern China.

Authors:  Xin-Qi Pei; Da-Lin He; Ge Tian; Wei Lv; Yu-Mei Jiang; Da-Peng Wu; Jin-Hai Fan; Kai-Jie Wu
Journal:  Int Urol Nephrol       Date:  2017-02-04       Impact factor: 2.370

7.  The effectiveness of the TAX 327 nomogram in predicting overall survival in Chinese patients with metastatic castration-resistant prostate cancer.

Authors:  Xiao-Jie Bian; Yao Zhu; Yi-Jun Shen; Jin-You Wang; Chun-Guang Ma; Hai-Liang Zhang; Bo Dai; Shi-Lin Zhang; Xu-Dong Yao; Ding-Wei Ye
Journal:  Asian J Androl       Date:  2013-07-01       Impact factor: 3.285

8.  Docetaxel with or without zoledronic acid for castration-resistant prostate cancer.

Authors:  Yue Pan; Haiyong Jin; Wei Chen; Zhixian Yu; Tingyu Ye; Yuancai Zheng; Zhiliang Weng; Feng Wang
Journal:  Int Urol Nephrol       Date:  2014-09-16       Impact factor: 2.370

9.  Clinical predictor of survival following docetaxel-based chemotherapy.

Authors:  Hsiang-Ying Lee; Wen-Jeng Wu; Chun-Hsiung Huang; Yii-Her Chou; Chun-Nung Huang; Yung-Chin Lee; Kai-Fu Yang; Mei-Hui Lee; Shu-Pin Huang
Journal:  Oncol Lett       Date:  2014-07-14       Impact factor: 2.967

10.  Expression of kallikrein-related peptidase 7 is decreased in prostate cancer.

Authors:  Chong-Yu Zhang; Yu Zhu; Wen-Bin Rui; Jun Dai; Zhou-Jun Shen
Journal:  Asian J Androl       Date:  2015 Jan-Feb       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.